Topics

Food and Drug Administration
In bid to lower costs, FDA OKs sale of 'biosimilar' knockoff of Amgen drug
In bid to lower costs, FDA OKs sale of 'biosimilar' knockoff of Amgen drug

The Food and Drug Administration approved the first copycat version of a biologic drug in the United States, allowing a Swiss company to sell a knockoff of Amgen Inc.’s chemotherapy recovery drug Neupogen. The FDA authorized Novartis' Sandoz unit to sell its version of the Amgen drug in the United States. Sandoz intends to market it under the brand name Zarxio. The decision is expected to pave the way for other “biosimilar” drugs to hit the U.S. market in coming years, a move that many say will lower drug costs by increasing competition. “Biosimilars will provide access to important therapies for patients who need them,” said FDA Commissioner Margaret...

Loading